Product Overview
[Drug name]
Generic name: H Irbesartan Tablets
Trade name: YiDaLi H Irbesartan Tablets 0.075g*12 tablets
Pinyin full code: YiDaLi HEBeiShaTanPian 0.075g*12Pian
[Main ingredients]
Chemical name: The main ingredient of this product is Irbesartan, and its chemical name is: 2-butyl-3-[4[2-(1H-tetrazolyl-5-yl)phenyl]benzyl]-1,3-diazaspiro[4,4]non-1-ene-4-one Molecular formula: C25H28N6O Molecular weight: 428.54
[Properties]
This product is a white to off-white film-coated tablet, oval biconvex, with HU engraved on one side and numbers 75 (0.075g rule), 150 (0.15g specification), 300 (0.3g specification) on the other side.
[Indications/Main functions]
Treatment of primary hypertension. Treatment of type 2 diabetic nephropathy with hypertension.
[Specification]
0.075g*12 tablets
[Usage and Dosage]
The recommended initial and maintenance doses are usually 150 mg per day, and diet has no effect on medication. In general, 150 mg of irbesartan once a day can better control 24-hour blood pressure than 75 mg. However, for some special patients, especially those undergoing hemodialysis and those over 75 years old, the initial dose can be considered 75 mg. Patients who cannot effectively control blood pressure with 150 mg of irbesartan once a day can increase the dose of this product to 300 mg, or add other antihypertensive drugs. In particular, the addition of diuretics such as hydrochlorothiazide has been shown to have an additive effect. In hypertensive patients with type 2 diabetes, the initial treatment dose should be 150 mg once a day, and the dose should be increased to 300 mg once a day as a better maintenance dose for the treatment of nephropathy. Clinical studies have shown that irbesartan benefits the kidneys of hypertensive type 2 diabetic patients. In the study, irbesartan was added with other antihypertensive drugs when necessary to lower the patient's blood pressure and reach the target value. Renal impairment: Patients with renal impairment do not need to adjust the dose of this product, but for patients undergoing hemodialysis, a low dose (75mg) can be considered as the initial dose. Hypovolemia: Patients with hypovolemia and/or sodium deficiency should correct it before using this product. Hepatic impairment: Patients with mild to moderate hepatic impairment do not need to adjust the dose of this product. There is currently no clinical experience for patients with severe hepatic impairment. Elderly patients: Although elderly people over 75 years old can consider starting with 75mg, it is usually not necessary to adjust the dose for elderly patients. Children: The safety and efficacy of irbesartan tablets in children have not been established.
[Adverse Reactions]
See the instructions for details.
[Contraindications]
Known allergy to the ingredients of this product. 4th to 9th month of pregnancy. Lactation. Patients with diabetes or moderate to severe renal impairment (GFR less than 60m/min/1.73m2) cannot use this product in combination with aliskiren. Patients with diabetic nephropathy cannot use this product in combination with angiotensin-converting enzyme inhibitors (ACEIs).
[Precautions]
See the instructions for details.
